Fan Lijuan, Zhong Zhenhao, Lin Yubo, Li Jitian
Henan Luoyang Orthopedic Hospital (Henan Provincial Orthopedic Hospital), Zhengzhou, Henan, China.
Luoyang Postgraduate Training Department, Henan University of Chinese Medicine, Zhengzhou, Henan, China.
Front Genet. 2022 Oct 19;13:1028477. doi: 10.3389/fgene.2022.1028477. eCollection 2022.
Osteosarcoma (OS) is a primary solid malignant tumor that occurs most frequently in the metaphysis of long bones. More likely to happen to children and adolescents. OS has high mortality and disability rate. However, the etiology and pathogenesis of OS have not been fully understood till now. Due to the lack of effective biomarkers, OS cannot be precisely detected in the early stage. With the application of next-generation and high-throughput sequencing, more and more abnormally expressed non-coding RNAs(ncRNAs) have been identified in OS. Growing evidences have suggested the ncRNAs, such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), have played an important role in the tumorigenesis and progression of OS. Thus, they can be served as novel biomarkers for diagnosis, treatment and prognosis. This review summarized the application of ncRNA as biomarkers in OS in detail, and discussed the limitation and future improvement of the potential biomarkers.
骨肉瘤（OS）是一种原发性实体恶性肿瘤，最常发生于长骨的干骺端。多见于儿童和青少年。骨肉瘤的死亡率和致残率很高。然而，骨肉瘤的病因和发病机制至今尚未完全明确。由于缺乏有效的生物标志物，骨肉瘤在早期无法得到精确检测。随着新一代高通量测序技术的应用，越来越多异常表达的非编码RNA（ncRNAs）在骨肉瘤中被鉴定出来。越来越多的证据表明，非编码RNA，如微小RNA（miRNAs）、长链非编码RNA（lncRNAs）、环状RNA（circRNAs），在骨肉瘤的发生发展过程中发挥了重要作用。因此，它们可作为诊断、治疗和预后的新型生物标志物。本文详细综述了非编码RNA作为生物标志物在骨肉瘤中的应用，并讨论了潜在生物标志物的局限性和未来改进方向。
